Shanghai Xuerong Biotechnology Co.,Ltd. (SHE:300511)
China · Delayed Price · Currency is CNY 7.01
-0.07 (-0.99%)
At close: Feb 13, 2026
SHE:300511 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,816 | 2,133 | 2,534 | 2,291 | 2,045 | 2,180 |
Other Revenue | 29.86 | 29.86 | 30.84 | 29.29 | 28.25 | 22.56 |
| 1,846 | 2,162 | 2,565 | 2,320 | 2,073 | 2,202 | |
Revenue Growth (YoY) | -18.40% | -15.70% | 10.55% | 11.93% | -5.86% | 12.10% |
Cost of Revenue | 1,752 | 2,129 | 2,409 | 2,102 | 2,024 | 1,734 |
Gross Profit | 94.42 | 33.76 | 156.48 | 218.31 | 49.16 | 468.48 |
Selling, General & Admin | 162.16 | 165.77 | 240.52 | 135.89 | 155.27 | 175.89 |
Research & Development | 2.83 | 3.46 | 6.84 | 7.49 | 13.56 | 11.85 |
Other Operating Expenses | 27.65 | 20.29 | 20.54 | 18.83 | 16.69 | -12.97 |
Operating Expenses | 198.24 | 195.54 | 270.7 | 164.83 | 183.3 | 174.52 |
Operating Income | -103.82 | -161.78 | -114.23 | 53.48 | -134.14 | 293.96 |
Interest Expense | -68.13 | -98.21 | -88.77 | -92.96 | -77.11 | -71.66 |
Interest & Investment Income | 1.81 | 2.47 | 8.27 | 18.43 | 7.49 | 8.9 |
Currency Exchange Gain (Loss) | 1.44 | 1.44 | 1.29 | 3.77 | -6.11 | 3.25 |
Other Non Operating Income (Expenses) | -3.03 | -1.39 | -4.71 | 7.68 | -0.81 | -0.13 |
EBT Excluding Unusual Items | -171.72 | -257.46 | -198.15 | -9.6 | -210.68 | 234.32 |
Gain (Loss) on Sale of Investments | -0.65 | -0.65 | -3.76 | -5.55 | - | - |
Gain (Loss) on Sale of Assets | 16.14 | 7.85 | 0.5 | -9.1 | -22.7 | -1.68 |
Asset Writedown | -378.77 | -377.71 | - | -364.16 | -139.17 | -16.83 |
Other Unusual Items | 18.47 | 11.56 | 9.32 | 7.86 | 16.91 | -10.82 |
Pretax Income | -516.53 | -616.41 | -192.1 | -380.55 | -355.65 | 204.99 |
Income Tax Expense | 0.76 | 0 | 0.24 | 13.57 | -4.49 | -3.24 |
Earnings From Continuing Operations | -517.29 | -616.41 | -192.33 | -394.12 | -351.15 | 208.22 |
Minority Interest in Earnings | 1.68 | -0.66 | 4.27 | 106.89 | 39.56 | 22.19 |
Net Income | -515.61 | -617.07 | -188.06 | -287.23 | -311.59 | 230.41 |
Net Income to Common | -515.61 | -617.07 | -188.06 | -287.23 | -311.59 | 230.41 |
Net Income Growth | - | - | - | - | - | 4.58% |
Shares Outstanding (Basic) | 550 | 498 | 495 | 487 | 433 | 435 |
Shares Outstanding (Diluted) | 550 | 498 | 495 | 487 | 433 | 435 |
Shares Change (YoY) | 10.55% | 0.55% | 1.66% | 12.49% | -0.46% | 0.63% |
EPS (Basic) | -0.94 | -1.24 | -0.38 | -0.59 | -0.72 | 0.53 |
EPS (Diluted) | -0.94 | -1.24 | -0.38 | -0.59 | -0.72 | 0.53 |
EPS Growth | - | - | - | - | - | 3.92% |
Free Cash Flow | 366.95 | 109.74 | -739.19 | 47.66 | -393.13 | 72.68 |
Free Cash Flow Per Share | 0.67 | 0.22 | -1.49 | 0.10 | -0.91 | 0.17 |
Dividend Per Share | - | - | - | - | - | 0.120 |
Gross Margin | 5.11% | 1.56% | 6.10% | 9.41% | 2.37% | 21.27% |
Operating Margin | -5.62% | -7.48% | -4.45% | 2.31% | -6.47% | 13.35% |
Profit Margin | -27.93% | -28.54% | -7.33% | -12.38% | -15.03% | 10.46% |
Free Cash Flow Margin | 19.88% | 5.08% | -28.82% | 2.05% | -18.96% | 3.30% |
EBITDA | 303.09 | 208.38 | 206.93 | 393.25 | 178.2 | 616.28 |
EBITDA Margin | 16.42% | 9.64% | 8.07% | 16.95% | 8.60% | 27.98% |
D&A For EBITDA | 406.91 | 370.16 | 321.16 | 339.77 | 312.33 | 322.32 |
EBIT | -103.82 | -161.78 | -114.23 | 53.48 | -134.14 | 293.96 |
EBIT Margin | -5.62% | -7.48% | -4.45% | 2.31% | -6.47% | 13.35% |
Revenue as Reported | 1,846 | 2,162 | 2,565 | 2,320 | 2,073 | 2,202 |
Advertising Expenses | - | 2.43 | 14.25 | 2 | 1.93 | 2.25 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.